An interventional study of Robotics Assisted Education + taVNS and Robotics Assisted Education + sham in Stroke Treatment and Stroke, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Stroke by Istanbul University - Cerrahpasa — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Istanbul University - Cerrahpasa.
Among the 22 studies in Stroke by Istanbul University - Cerrahpasa, this one is the 14th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is one of 18 with no phase, and was the 21st registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →3 of the 22 studies in Stroke by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–75
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–70
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 30 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 41 across the 18 interventional studies, 44 across the 4 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.
2 of the studies in Stroke by Istanbul University - Cerrahpasa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725211Istanbul University - CerrahpasaTask-Oriented Training Versus High-Intensity Gait Training in People With Chronic Stroke | 2026-12-15 |
| NCT07257107Istanbul University - CerrahpasaEffect of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Upper Extremity Robot-Assisted Training on Upper Extremity Motor Functions in Stroke Patients | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Stroke by Istanbul University - Cerrahpasa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The effects of stroke on the upper extremity are a common and significant cause of long-term disability, with 65% of patients reporting an inability to participate in daily activities with the affected upper extremity after 6 months. Robotic-assisted training (RAT) has been widely used in recent years to improve upper extremity function. RAT positively impacts upper extremity function and activities of daily living by inducing motor learning from intense, highly repetitive, and task-focused movements of the upper extremity. However, current, limited clinical solutions, including minimally invasive transcutaneous auricular vagus nerve stimulation (taVNS), have not yielded promising results. Therefore, the aim of this study was to investigate the effects of the combination of taVNS and RTA on motor impairment, upper extremity motor function, grip strength, daily living characteristics, and quality of life in individuals with stroke. Stroke medications were randomly assigned to RDE+taVNS (n=15) and RDE+sham taVNS (n=15). All participants will receive conventional treatment for 45 minutes per day, 3 days per week, for 5 weeks. One group will also receive RDE+taVNS treatment for 45 minutes per day, 2 days per week, for 5 weeks, while the other group will receive RDE+sha taVNS. Participants will be assessed using the Fugl-Meyer Upper Extremity Assessment, ARAT (Action Research Arm Test), and Box and Block Test as primary outcomes at baseline and after 5 weeks.
This project will contribute to the literature by demonstrating the effectiveness of taVNS, one of the most promising methods available. Furthermore, the results will prompt discussion on the applicability of the method not only to stroke patients but also to other disease groups. The unique value of this project is that it is the first study to investigate product improvements in taVNS systems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Robotics Assisted Education + taVNS
Other: Robotics Assisted Education + sham
Conventional rehabilitation will be administered 3 days a week, 45 minutes per day, for 5 weeks. The combination of Upper Extremity Robotic-Assisted Training and Transcutaneous Auricular Vagus Nerve Stimulation will be administered 2 days a week, 45 minutes per day, for 5 weeks.
Conventional rehabilitation will be administered 3 days a week, 45 minutes per day, for 5 weeks. The combination of Upper Extremity Robotic-Assisted Training and Sham Transcutaneous Auricular Vagus Nerve Stimulation will be administered 2 days a week, 45 minutes per day, for 5 weeks.
Fugl Meyer Upper Extremity Evaluation (FM-UE)
We will use the Fugl-Meyer Upper Motor Assessment score, which is the most sensitive for treatment outcomes in stroke patients presenting with unilateral paresis in the post-stroke period. It measures upper extremity use and impairment, measuring shoulder, elbow, forearm, wrist, finger, and reflex movements from proximal to distal, synergistic to extrinsic. The score ranges from 0 to 66 and consists of 33 items. 0-28 indicates severe motor impairment; 29-42 indicates moderate motor impairment; and 43-66 indicates mild motor impairment. Higher scores indicate better performance. The FM-UE consists of one component, each rated on a 3-point ordinal scale (0=not achieved, 1=partially contributed, 2=completely contributed). The minimum clinically meaningful change on the FM-UE for chronic stroke has been determined to be 4.25 to 7.25. Consistent with the literature, we define an improvement of at least 6 points or more as significant.
Time frame: Outcome measures will be assessed and recorded at baseline (assessment session) and after intervention (week 5).
Box and Block Test (BBT)
The Box and Block Test is a manual dexterity test used to assess upper extremity motor function. It primarily assesses gross motor function. It is calculated by the number of 2.5 cm3 blocks thrown from one side to the other in 1 minute. A box and block test kit has been prepared to meet international standards.
Time frame: Outcome measures will be assessed and recorded at baseline (assessment session) and after intervention (week 5).
Hand Grip Strength
Grip strength on the affected side will be measured with a Jamar Hydraulic Dynamometer. The measurement protocol will be explained and demonstrated to the participant by an experienced physiotherapist. The dynamometer grip size will be adjusted to the participant's hand size, and the participant will be asked to squeeze the dynamometer for a practice trial. Anti-gravity support will be provided to maintain the position if necessary. Grip strength measurements with the Jamar dynamometer have proven to be highly valid and reliable, and normative values have been published.
Time frame: Outcome measures will be assessed and recorded at baseline (assessment session) and after intervention (week 5).
Stroke Impact Scale (SIS)
The SIS 3.0 assesses function and quality of life based on subjective report in eight clinically important domains. It consists of two parts. The first part is the main scale of the IAS, which assesses multidimensional health-related quality of life (QOL) including strength, hand function, ADL/instrumental ADL, mobility, communication, emotion, memory/thinking, and social participation. It consists of 59 items, and each item is subjectively rated by stroke patients on a 5-point Likert-type scale according to their perceived difficulty with the item in the past week. The score for each domain is converted to a score out of 100, and the average scores for all domains are used to represent stroke patients' multidimensional health-related quality of life. The formula Domain Score = \[(Average Item Score -1) / (5 -1) x 100\] is used to convert each domain score. SIS 3.0 also includes assessment of post-stroke recovery using a 0-100 visual analog scale (0: no recovery, 100: complete recovery)
Time frame: Outcome measures will be assessed and recorded at baseline (assessment session) and after intervention (week 5).
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 17 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →